ADME/DMPK Services for Brain Tumors

ADME/DMPK, encompassing absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics, is critical in the development of effective therapies for brain tumors. At Alfa Cytology, we specialize in providing comprehensive ADME/DMPK services tailored to the specific needs of brain tumor research.

Introduction to ADME/DMPK

Understanding these pharmacokinetic properties is essential for optimizing drug formulations and ensuring that therapeutic agents reach their intended targets within the central nervous system. Given the unique challenges posed by the blood-brain barrier and the complex biology of brain tumors, a thorough evaluation of ADME/DMPK properties is imperative for the success of any new treatment.

Our Services

At Alfa Cytology, we offer specialized ADME/DMPK services tailored for brain tumor research. Our comprehensive suite of services is designed to address the unique challenges of CNS pharmacology and ensure that our clients can effectively develop and evaluate their drug candidates.

In Vitro ADME Services for Brain Tumors

ADME characterizes how therapies act in the body. Alfa Cytology supports researchers in predicting and selecting optimal cancer therapies by offering a wide range of in vitro ADME studies. These protocols provide initial insights into therapy behavior in vivo, aiding drug development and research.

Absorption

PAMPA (GIT, BBB and Skin)
Caco-2 Permeability
MDCK MDR1 Permeability
MDCK BCRP Permeability

Distribution

Plasma / Blood Partitioning
Blood Brain Barrier Penetration
Brain Tissue Binding
Microsomal Binding
Plasma Protein Binding

Metabolism

Liver Microsomes
Hepatocytes
Liver S9 Fractions
Plasma Binding Stability
Metabolic Pathway and Metabolites Identification

Excretion

Renal Tubule Cell Assay System
Biliary Excretion Assays
Transporter Assays
In Vitro Dialysis Assays

In Vivo PK Services for Brain Tumors

Blood-Brain Barrier (BBB) Penetration Assessment

Quantification of drug concentrations in brain parenchyma vs. plasma.
Calculation of brain-to-plasma ratios (K_p, K_p,uu).

Integrated PK/Toxicity Profiling

Correlation of CNS drug exposure with neurotoxicity markers.
BBB integrity assessment (Evans Blue, IgG leakage).

Brain Tissue Distribution Studies

Microdialysis: Real-time monitoring of free drug in brain ECF.
QWBA (Quantitative Whole-Body Autoradiography): Spatial drug distribution in brain sections.
LC-MS/MS-based Tissue Homogenate Analysis.

Intracranial Tumor PK/PD Modeling

PK sampling from orthotopic brain tumor models (e.g., glioblastoma PDX, syngeneic grafts).
Correlation of tumor drug exposure with efficacy biomarkers.

Services Workflow

The workflow at Alfa Cytology is designed to provide a seamless experience for our clients, ensuring that all aspects of ADME/DMPK services are meticulously addressed.

Inquiry

Clients provide detailed information regarding their drug candidates and research objectives.

Project Design

Our experts collaborate with clients to design tailored experimental protocols that meet specific research needs.

Development

Conduct in vitro and in vivo studies according to approved protocols, utilizing state-of-the-art laboratory technologies.

Data Analysis

Comprehensive data analysis is performed to interpret results, with a focus on pharmacokinetic parameters and metabolic profiles.

Result Delivery

Clients receive detailed reports encompassing methodologies, data interpretations, and recommendations for further development.

Contact Us

For more information on our ADME/DMPK services for brain tumors, or to discuss how Alfa Cytology can assist you in your research and development endeavors, please fell free to contact us. Our team of experts is ready to assist you with any inquiries and to discuss how our services can be tailored to meet your specific research needs.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.